Filing Flows › TG Therapeutics (TGTX) › Q1 2026
TG Therapeutics (TGTX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
TG Therapeutics (TGTX) reported revenue of $205M for the first quarter 2026 (Q1 2026), +70% from a year earlier and +6% from the quarter before. Operating margin was 17.0%, net earnings $19.8M (9.7% of revenue).
TG Therapeutics, Q1 2026: revenue $205M (+70% year over year), operating margin 17.0%, net earnings $19.8M, operating cash flow −$17.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $205M | +6% | +70% |
| Operating profit | $34.8M | -31% | +304% |
| Net earnings | $19.8M | -14% | +291% |
| Operating cash flow | −$17.9M | -191% | — |
What changed
Revenue was $204.9M in Q1 2026, up 70% year over year and up 6% from the previous quarter. Product was the largest line at 98% of revenue. Product added $81.7M year over year (up 68%), 97% of the total change.
Operating profit was $34.8M, a 17.0% margin (up 9.8 points year over year). Of the extra revenue versus Q1 2025, 31% reached operating profit, above the 7% margin then. Total costs grew 52% against revenue growth of 70%. The fastest-growing cost line was Cost of revenue (+116%). Net earnings were $19.8M, up 291% year over year. The effective tax rate was 2.9%.
Operating cash flow was −$17.9M. Non-cash charges added back $32K of depreciation and amortization and $19.9M of share-based compensation. Working capital and other items used $57.7M. Capital expenditures of $51K exceeded it, leaving free cash flow of −$17.9M.
Questions
What was TG Therapeutics' revenue in the first quarter 2026?
TG Therapeutics (TGTX) reported revenue of $205M for the first quarter 2026 (Q1 2026), +70% from a year earlier and +6% from the quarter before.
Was TG Therapeutics profitable in the first quarter 2026?
Operating profit was $34.8M (17.0% of revenue) and net earnings $19.8M.
Source: TG Therapeutics 10-Q on SEC EDGAR.